10/22/2025
Elinzanetant shows long-term safety in study for hot flashes.
Bayer has released results from a Phase III study showing the long-term safety and effectiveness of elinzanetant for menopausal hot flashes. The study, published in JAMA Internal Medicine, showed that elinzanetant significantly reduced vasomotor symptoms over 52 weeks without liver damage. The drug has already been approved in the UK and Canada under the name Lynkuet, but US approval has been delayed until late October.
Full Story: United Press International